Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


Vitae Pharmaceuticals, Inc.

Unaudited Condensed Statements of Cash Flows

 
  Six Months Ended June 30,  
 
  2014   2013  

Operating activities:

             

Net loss

  $ (10,019,050 ) $ (8,723,330 )

Adjustment to reconcile net loss to net cash (used in) provided by operating activities:

             

Depreciation and amortization

    102,162     114,070  

Stock-based compensation

    112,058     57,014  

Deferred rent and lease incentives

    572     (5,156 )

Amortization of deferred financing fees

    109,417     109,417  

Revaluation of preferred stock warrant liability

    (175,750 )   (219,500 )

(Gain) loss on disposal of equipment

    (2,500 )   67  

Changes in assets and liabilities:

             

Accounts receivable

        8,740,000  

Prepaid expenses and other current assets

    188,102     18,019  

Accounts payable and accrued expenses

    223,695     537,725  

Deferred revenue

    (2,000,000 )   3,056,307  

Interest payable

    20,299     24,913  
           

Net cash (used in) provided by operating activities

    (11,440,995 )   3,709,546  
           

Investing activities:

             

Purchases of property and equipment

    (126,981 )   (140,741 )

Proceeds from disposal of equipment

    2,500     700  

Purchases of investments

    (13,367,685 )   (18,494,433 )

Sales of investments

    15,243,922     17,042,000  
           

Net cash provided by (used in) investing activities

    1,751,756     (1,592,474 )
           

Financing activities:

             

Principal payments under debt facilities

    (2,671,298 )   (2,045,653 )

Payment of deferred offering costs

    (114,779 )    

Restricted cash

        250,000  

Proceeds from the issuance of common stock, net of repurchases

    38,268     36,360  
           

Net cash used in financing activities

    (2,747,809 )   (1,759,293 )
           

Net (decrease) increase in cash and cash equivalents

    (12,437,048 )   357,779  

Cash and cash equivalents at beginning of period

    21,155,247     7,629,143  
           

Cash and cash equivalents at end of period

  $ 8,718,199   $ 7,986,922  
           
           

Supplemental disclosures of cash flow information:

             

Cash paid for interest

  $ 411,321   $ 633,885  
           
           

   

The accompanying notes are an integral part of these unaudited condensed financial statements.

F-36